Home Effect of 13-cis-retinoic acid on the genetic expression profile of human umbilical vein endothelial cells (HUVECs) determined by microarray
Article
Licensed
Unlicensed Requires Authentication

Effect of 13-cis-retinoic acid on the genetic expression profile of human umbilical vein endothelial cells (HUVECs) determined by microarray

  • Juliana Salazar , Mercedes Camacho , Lluís Masana , Luis Vila and Josep Ribalta
Published/Copyright: July 8, 2007
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 45 Issue 7

Abstract

Background: Treatment with isotretinoin (13-cis-retinoic acid; 13-cis RA) has been associated with hypertriglyceridemia and low levels of high-density lipoprotein (HDL)-cholesterol, which are well-established cardiovascular risk factors. The development of hypertriglyceridemia secondary to this treatment could predispose to the metabolic syndrome. Hence, because of the risk of atherosclerosis associated with this treatment and to help unravel the underlying mechanisms involved, we studied the effect of 13-cis RA on genetic expression in endothelial cells.

Methods: Total RNA was isolated from human umbilical vein endothelial cells (HUVECs) treated without 13-cis RA (control) or incubated with 13-cis RA (1 μM) for 6 and 24 h. Microarray analysis (Affymetrix U133A array) with >22,000 probes was used with real time RT-PCR of a series of genes selected because of their involvement in the RA signaling pathway.

Results: The treatment of endothelial cells with 13-cis RA produced significant changes in the expression of genes implicated in cell adhesion and in lipid metabolism processes, specifically in the clearance of lipoprotein remnant particles and in HDL metabolism.

Conclusions: Isotretinoin in the endothelium has an exacerbating effect on atherosclerosis risk factors. This is especially relevant in the regulation of expression of genes involved in the processes of cell adhesion and lipid metabolism.

Clin Chem Lab Med 2007;45:829–34.


Corresponding author: Josep Ribalta, PhD, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, C/ Sant Llorenç, 21, 43201 Reus, Spain Phone: +34-977-759390, Fax: +34-977-759322

Received: 2006-11-16
Accepted: 2007-1-15
Published Online: 2007-07-08
Published in Print: 2007-07-01

©2007 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Pharmacogenomics and Personalized Medicine – a global reality check
  2. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice
  3. Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy
  4. Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer
  5. Effect of 13-cis-retinoic acid on the genetic expression profile of human umbilical vein endothelial cells (HUVECs) determined by microarray
  6. Association between T102C and A–1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs
  7. A1166C polymorphism of the angiotensin AT1 receptor (AT1R) gene alters endothelial response to statin treatment
  8. Third Santorini conference pharmacogenomics workshop report: “Pharmacogenomics at the crossroads: what else than good science will be needed for the field to become part of Personalized Medicine?”
  9. On detecting interference from endogenous antibodies in immunoassays by doubling dilutions test
  10. High-sensitivity C-reactive protein concentration in patients with myocardial infarction-environmental factors, and polymorphisms in interleukin-10 and CD14 genes
  11. Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience
  12. A novel application of melting curves: utility of peak area calculation for relative methylation quantification
  13. Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians
  14. Tumor necrosis factor-α and oxidant status are essential participating factors in unexplained recurrent spontaneous abortions
  15. Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of β-thalassemia/hemoglobin E patients
  16. Analysis of glomerular filtration rate, serum cystatin C levels, and renal resistive index values in cirrhosis patients
  17. Direct determination of selenium in human serum by inductively coupled plasma-collision cell-mass spectrometry
  18. Within-subject variation of plasma resistin levels over a 1-year period
  19. Global DNA methylation measured by liquid chromatography-tandem mass spectrometry: analytical technique, reference values and determinants in healthy subjects
  20. Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population
  21. Comparison of the Roche COBAS Amplicor™ Monitor, Roche COBAS Ampliprep™/COBAS Taqman™ and Abbott RealTime™ Test assays for quantification of hepatitis C virus and HIV RNA
  22. Genetic cystic fibrosis transmembrane regulator 4016insT D1152H compound heterozygosity and male infertility: an Italian case report
  23. Reference intervals for serum cystatin C in healthy Mexican adults
  24. Could standard ISO 15189 be useful for the conundrum of CA 19-9/GI Monitor measurement?
  25. Quality control strategy to verify day-to-day imprecision of length of blood sedimentation reaction measurements with the TEST-1 analyzer
  26. Applicability of α-fetoprotein-concanavalin A (AFP-ConA) binding to discriminate between germinal or hepatic origin of AFP in germ cell tumour patients during chemotherapy or follow-up
  27. Proposal of a candidate international conventional reference measurement procedure for free thyroxine in serum
  28. Balkan Clinical Laboratory Federation − past, present and future trends
Downloaded on 15.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2007.139/html
Scroll to top button